Clinical trials: Antibody Mediated
HER2-positive Breast Cancer, Operable Breast Cancer
Impact of Pegfilgrastim on Trastuzumab Anti-tumor Effect and ADCC in Operable HER2+ Breast Cancer Breast Cancer
First preclinical data suggest that pegfilgrastim could constitute a potent adjuvant for immunotherapy with mAb possessing ADCC/ADCP properties as trastuzumab.
- Trial name
- BREASTIMMU02 (NCT03571633)
- Testing
- Trastuzumab + Paclitaxel, Pegfilgrastim
- Where
- 9 sites in France
- Volunteers
- 90 people
- Sponsor
- Centre Leon Berard
Antibody-mediated Rejection, Hyperacute Rejection of Cardiac Transplant
The De-novo Use of Eculizumab in Presensitized Patients Receiving Cardiac Transplantation
All individuals who receive a heart transplant are at risk for developing antibody-mediated rejection (AMR). An antibody is a protein produced by the body's immune system when it detects a foreign substance, called an antigen.
- Conditions
- Antibody-mediated Rejection, Hyperacute Rejection of Cardiac Transplant, Left Ventricular Dysfunction, Cardiac Allograft Vasculopathy
- Trial name
- DUET (NCT02013037)
- Testing
- Eculizumab
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Cedars-Sinai Medical Center
Polyneuropathies
Rituximab to Treat Neuropathy With Anti-MAG Antibodies
This study will test the safety and effectiveness of the drug Rituximab in treating a nerve disease called MGUS (also known as neuropathy with anti-MAG antibodies).
- Trial name
- NCT00050245
- Testing
- Rituximab
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Antibody-Mediated Graft Rejection
Cell-based Assays for Antibody-mediated Transplant Rejection
Goal: The goal of this study is to validate blood tests, which can detect antibody-mediated rejection (ABMR) after renal transplantation.
- Trial name
- NCT03916822
- Testing
- Alloantigen-specific B-cells
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Plexision
Kidney Transplant Rejection
Pilot Study of Treatment for Subclinical AMR (Antibody-mediated Rejection) in Kidney Transplant Recipients
This is a pilot study to determine if extended release Envarsus at an optimal level is just as effective as more invasive standard therapies for subclinical (mild) AMR (antibody mediated rejection) in kidney transplant patients.
- Trial name
- NCT03380936
- Testing
- Tacrolimus Extended Release Oral Tablet [Envarsus], Plasma Exchange and IVIG (Intravenous Immunoglobulin )
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- University of Colorado, Denver
Neuroblastoma
Iodine I 131 Monoclonal Antibody 3F8 and Bevacizumab in Treating Patients With Relapsed or Refractory Neuroblastoma
RATIONALE: Monoclonal antibodies, such as iodine I 131 monoclonal antibody 3F8 and bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00450827
- Testing
- bevacizumab, filgrastim, autologous hematopoietic stem cell transplantation
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Transplant; Complication, Rejection
Mechanistic Evaluation of Treatments for Acute Antibody-Mediated Rejection of the Kidney Transplant
The best treatment for kidney failure is a kidney transplant, but a transplanted kidney only works for about 10 to 15 years on average.
- Trial name
- MOT-AMR (NCT04496037)
- Testing
- Rituximab
- Volunteers
- 170 people
- Sponsor
- Imperial College London
Blood Disease, Platelet Refractoriness
HPA Antibodies and the Distribution of Antigen and Antibodies
By detecting platelet antibodies of participants and then further to identify their genotype and analyzing laboratory examination, the investigators will obtain positive frequency of HPA antibodies, the distribution of HPA…
- Conditions
- Blood Disease, Platelet Refractoriness, Antibody-mediated Rejection
- Trial name
- NCT03408158
- Testing
- same type infusion of main HPA antigen
- Where
- China
- Volunteers
- 6,170 people
- Sponsor
- Guangzhou First People's Hospital
Refractory Immune-mediated Platelet Transfusion Refractoriness, Relapsed or Refractory Immune Thrombocytopenia
RN1201 Injection in the Treatment of Antibody-Mediated Diseases
This single-arm, open-label exploratory trial aims to evaluate the safety, feasibility, and preliminary efficacy of RN1201 Injection in patients with antibody-mediated diseases, including refractory immune-mediated platelet…
- Trial name
- NCT07072247
- Testing
- CD19 and BCMA-targeted allogeneic CAR-T cells
- Where
- China
- Volunteers
- 9 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Food Allergy, Food Allergy in Infants
The Egg Up Trial - Testing a New Treatment Pathway for Infants With Newly Diagnosed Egg Allergy
The goal of this study is to test the safety and feasibility of a change in management approach for infants with newly diagnosed egg allergy.
- Trial name
- NCT06273605
- Testing
- Egg Ladder
- Where
- Australia
- Volunteers
- 109 people, healthy volunteers welcome
- Sponsor
- Murdoch Childrens Research Institute
Graft Rejection
Randomized Trial for Mixed Acute Rejection
This study is being conducted to determine how safe and effective using an immune cell (b cell) depleting therapy and/or Thymoglobulin is in patients with a kidney transplant who are experiencing certain types of rejection.
- Trial name
- NCT00771875
- Testing
- Rabbit Antithymocyte Globulin (RATG), Rituximab, Bortezomib
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- University of Cincinnati
Antibody-mediated Rejection, Allosensitization
Isatuximab in Lung Transplant Recipients
The purpose of this study is to determine the safety and feasibility of adding isatuximab to standard of care therapies in patients who will receive a lung transplant, but have significant antibodies against the donor…
- Trial name
- NCT05862766
- Testing
- Isatuximab, bone marrow biopsy
- Where
- United States
- Sponsor
- NYU Langone Health
Kidney Transplant Rejection, Antibody-mediated Rejection
Transplant Antibody-Mediated Rejection: Guiding Effective Treatments
This trial evaluates the addition of rituximab to standard of care in the treatment of antibody-mediated rejection in kidney transplant patients. The trial will involve adults and children.
- Trial name
- TAR:GET-1 (NCT03994783)
- Testing
- Rituximab, Methylprednisolone, Intravenous Immunoglobulin
- Where
- United Kingdom
- Volunteers
- 3 people
- Sponsor
- Imperial College London
Peanut Allergy
Efficacy and Safety of Viaskin Peanut in Children With Immunoglobulin E (IgE)-Mediated Peanut Allergy
The PEPITES study evaluates the efficacy and safety of Viaskin Peanut 250 µg peanut protein to induce desensitization to peanut in peanut-allergic children 4 through 11 years of age after a 12-month treatment by epicutaneous…
- Trial name
- PEPITES (NCT02636699)
- Testing
- Viaskin Peanut 250mcg
- Where
- 31 sites in United States, Australia and 3 more
- Volunteers
- 500 people
- Sponsor
- DBV Technologies
Cow's Milk Allergy
Evaluation of Tolerance, Efficacy and Safety of an Hydrolyzed Formula in Infants With IgE/Non-IgE Mediated CMA.
The aim of this interventional study is to assess the hypoallergenicity of a new formula in infants having a cow milk allergy (CMA), whatever the type of CMA, meaning in both IgE-mediated and non-IgE-mediated CMA patients.
- Trial name
- MERLIN (NCT06481280)
- Testing
- Test Formula
- Where
- 2 sites in Belgium, Italy
- Volunteers
- 70 people
- Sponsor
- United Pharmaceuticals
Allosensitization, Kidney Transplant Rejection
Desensitization in Kidney Allograft Using Daratumumab
Patients highly allosensitized against HLA antigen awaiting for a kidney transplant have less compatible transplants to them, increasing their waitlist time and mortality.
- Conditions
- Allosensitization, Kidney Transplant Rejection, Antibody-mediated Rejection
- Trial name
- DARDAR (NCT04204980)
- Testing
- Daratumumab dose escalation, Daratumumab full dose
- Where
- France
- Volunteers
- 21 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Pericarditis, Tako-TSUBO Cardiomyopathy
Inflammatory Disease Biobank for Immunophenotyping and Cardiovascular Research
INFLAME-BANK is a French multicenter prospective observational ancillary study of the international EACVI-INFLAME project. It aims to establish a biobank and perform immunophenotyping and proteomic analyses in patients with…
- Conditions
- Pericarditis, Tako-TSUBO Cardiomyopathy, Myocarditis, Inflammatory Cardiomyopathies
- Trial name
- INFLAME-BANK (NCT07737470)
- Volunteers
- 300 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Antibody-mediated Rejection
Efficacy and Safety of Human Plasma-derived C1-esterase Inhibitor as add-on to Standard of Care for the Treatment of Refractory Antibody Mediated Rejection (AMR) in Adult Renal Transplant Recipients
This is a double-blind, randomized-withdrawal, placebo-controlled study in kidney transplant patients with AMR to evaluate the efficacy and safety of human plasma-derived C1-esterase inhibitor as add-on to standard of care (IVIG).
- Trial name
- NCT03221842
- Testing
- C1-esterase inhibitor
- Where
- 26 sites in United States, Belgium and 5 more
- Volunteers
- 63 people
- Sponsor
- CSL Behring
Lung Transplant Recipient, Donor Specific Antibodies
DSA Intragraft in Lung Transplantation: Diagnostic and Prognostic Value in Antibody Mediated Rejection
The diagnosis of AMR in lung transplant recipients is difficult and often comes too late, because of lack of standardized definition.
- Conditions
- Lung Transplant Recipient, Donor Specific Antibodies, Antibody Mediated Rejection
- Trial name
- NCT03702257
- Testing
- bronchoscopy.
- Where
- 5 sites in France
- Volunteers
- 80 people
- Sponsor
- University Hospital, Strasbourg, France
Hypersensitivity, Beta Lactam Adverse Reaction
Protocol of Reintroduction of Beta-lactams in Children at Low Risk of Anaphylaxis.
The purpose of this study is to establish the rationale for the practice of performing an oral reintroduction test without previous skin tests in children at low risk of IgE-mediated reaction or drug-induced toxidermia, and to…
- Trial name
- TRO-b-lact (NCT03553251)
- Where
- France
- Volunteers
- 195 people, healthy volunteers welcome
- Sponsor
- Nantes University Hospital